PsychiatricTimes Members: Login | Register

|     

PsychiatricTimes SearchMedica Medline Drugs

Powered by SearchMedica

 
Risk Assessment
News
Current Issues
Blogs
Special Reports
CME
Conferences
Resources
Careers
Multimedia
About Us
 


Psychiatric Times. Vol. 30 No. 1
Pages: 1  2  3  4  
Previous Next
COMORBIDITIES 

Identifying and Treating Common Psychiatric Conditions Comorbid with Myalgic Encephalomyelitis and/or Fibromyalgia

By Eleanor Stein, MD | January 18, 2013
Dr Stein is Clinical Assistant Professor in the department of psychiatry at the University of Calgary, Calgary, Alberta, and is in private practice dedicated to the treatment of myalgic encephalomyelitis/chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivity. She reports no conflicts of interest concerning the subject matter of this article.

Low doses of sedating antidepressants are commonly used off-label in both ME and FM to improve sleep initiation and duration.23,24 It should be noted that the effect sizes of antidepressant effects in FM are small and “a remarkable number of patients drop out of therapy because of intolerable adverse effects or experience only a small relief of symptoms, which does not outweigh the adverse effects.”21 Symptomatic management remains the mainstay of treatment.25,26

In patients with ME or FM, psychotropic medication is indicated if the psychiatric symptoms are severe enough to interfere with hope, sleep, and/or self-management. For example, a person may be so hopeless that he or she does not have the motivation to make the lifestyle changes that would improve pain and other symptoms. Psychiatric medications work best in patients with comorbid psychiatric conditions and less well when anxiety or depressive symptoms, which are reactions to adverse life events, are coincident with the ME or FM. For the comorbid group, one treats the same as for any other psychiatric patient, using current treatment guidelines. All classes of drugs, including antipsychotics, antidepressants, and mood stabilizers, are appropriate, depending on the diagnosis.

(MORE: Comorbid Movement and Psychiatric Disorders)

Anticonvulsants such as lamotrigine(Drug information on lamotrigine) and topiramate(Drug information on topiramate) can be helpful as mood stabilizers and because of their antinociceptive effects. Although pregabalin(Drug information on pregabalin) is effective for FM pain, gabapentin(Drug information on gabapentin) is less so. Neither has significant psychotropic properties but can be useful as a sleep aid. Buspirone(Drug information on buspirone) is an option as an anxiolytic, but effectiveness is modest.

Because of adverse effects (eg, tolerance, withdrawal symptoms), I avoid use of benzodiazepines except in cases of severe anxiety or muscle spasm that has failed to respond to other treatment approaches. Benzodiazepines are a last choice for treatment of ME and FM.

It is accepted (though not proved) that in patients with ME and FM, psychotropic medications usually need to be started at lower doses than those tolerated by physically healthy patients. In some patients, usual therapeutic doses can be reached; in other patients, full dose is not possible because of the severity of adverse effects. Some patients are unable to tolerate any antidepressant. For these patients, there are a couple of nonpharmacological approaches that may, with care, be used alone or to augment antidepressant effects.

Eicosopentanoic acid (EPA). EPA is an omega-3 fatty acid found in fish oil. A recent meta-analysis shows that EPA is an effective treatment for MDD at dosages of 200 to 2000 mg/d.27 A recent study reported that EPA is equally as effective as fluoxetine(Drug information on fluoxetine).28 In my experience, relatively high dosages of EPA, at least 4000 mg/d, are necessary for robust antidepressant effect. EPA is not effective for anxiety. Checking the Web site of the International Fish Oil Standards Program is advised to ensure that a fish oil product meets purity standards.29

St John’s wort. This herbal remedy has strong SSRI properties and has been found to be equally as effective as SSRI drugs in treating MDD.30,31 St John’s wort is taken as a standardized 0.3% extract of hypericin 300 mg by mouth 3 times daily. It should be noted, however, that St John’s wort has many adverse effects and a long list of drugs and other herbal supplements with which it can interact adversely. In combination with other antidepressants or neurotransmitter precursors, serotonin syndrome can occur.

Pages: 1  2  3  4  
Previous Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.

  • Oldest First
  • Newest First

by James OBrien | February 14, 2013 12:18 PM EST

All these articles on comorbidity probably means that these categories aren't constructionally valid in the first place.

BTW, Frederick Wolfe MD, who described FM during its origins, has recanted and now states it is not a disease.

Also in this Special Report

Introduction: The Integrated Approach to Addressing Comorbidities—Part 1

Comorbidities in Borderline Personality Disorder

Identifying and Treating Common Psychiatric Conditions Comorbid with Myalgic Encephalomyelitis and/or Fibromyalgia

Migraine and Psychiatric Comorbidity

Treatment Implications for Comorbid Diabetes Mellitus and Depression

Comorbid Movement and Psychiatric Disorders





 
What Your Colleagues Are Reading...

Sexual Addiction: Diagnosis and Treatment
Psychiatric Times,  October 1, 1998
Psychopathy and Antisocial Personality Disorder: A Case of Diagnostic Confusion
Psychiatric Times,  February 1, 1996
Does Marijuana Withdrawal Syndrome Exist?
Psychiatric Times,  February 1, 2002
People Who Hoard Animals
Psychiatric Times,  April 1, 2000
Are Genius and Madness Related? Contemporary Answers to an Ancient Question
Psychiatric Times,  May 31, 2005
 
What's New in Psychiatry

The Psychiatrist and the Slot Machine
Psychiatric Times,  May 24, 2013
The Role of Biological Tests in Psychiatric Diagnosis
Psychiatric Times,  May 23, 2013
You Are—And Your Mood Is—What You Eat
Psychiatric Times,  May 23, 2013
Experts Discuss Changes, Updates in DSM-5
Psychiatric Times,  May 22, 2013
The Paradox of Choice: When More Medications Mean Less Treatment
Psychiatric Times,  May 22, 2013




CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy